Publikationen

Aktuelle Publikationen

• Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, Cervera J, Lea N, Ferrero D, Germing U, Hildebrandt B, Martínez ABV, Santini V, Sanz GF, Solé F, Mufti GJ. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. 2020. Leukemia.
• A Kuendgen, M Nomdedeu, H Tuechler, G Garcia-Manero, R S Komrokji, M A Sekeres, M G Della Porta, M Cazzola, A E DeZern, G J Roboz, D P Steensma, A A Van de Loosdrecht, R F Schlenk, J Grau, X Calvo, S Blum, A Pereira, P Valent, D Costa, A Giagounidis, B Xicoy, H Döhner, U Platzbecker, C Pedro, M Lübbert, I Oiartzabal, M Díez-Campelo, M T Cedena, S Machherndl-Spandl, M López-Pavía, C D Baldus, M Martinez-de-Sola, R Stauder, B Merchan, A List, C Ganster, T Schroeder, M T Voso, M Pfeilstöcker, H Sill, B Hildebrandt, J Esteve, B Nomdedeu, F Cobo, R Haas, F Sole, U Germing, P L Greenberg, D Haase, G Sanz. Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS. 2020. Leukemia.
• Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020. 136(2):157-170.

Publikationen 2019

• Haase D. Klonale Hämatopoese - Teil 1. best practice onkologie. 2019. 14(5):166-79.
• Haase D. Klonale Hämatopoese - Teil 2. best practice onkologie. 2019. 14(9):360-72.
• Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes Cancer. 2019. 58(10):689-697.
• Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. International Working Group for MDS Molecular Prognostic Committee. Leukemia. 2019. 33(7):1747-1758.

Publikationen 2018

• Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes Cancer. 2018. 57(11):547-556.
• Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D. Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. Am J Hematol. 2018. 93(6):E152-E154.
• Schanz J, Cevik N, Fonatsch C, Braulke F, Shirneshan K, Bacher U, Haase D. Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. Blood Cancer J. 2018. 8(3):28.

Publikationen 2017

• Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Ann Hematol. 2017. 96(6):887-894.

Publikationen 2016

• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016. 128(16):2096-2097.

Publikationen 2015

• Ganster C, Kämpfe D, Jung K, Braulke F, Shirneshan K, Machherndl-Spandl S, Suessner S, Bramlage CP, Legler TJ, Koziolek MJ, Haase D, Schanz J. New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes. Genes Chromosomes Cancer. 2015. 54(12):717-24.
• Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. Genes Chromosomes Cancer. 2015. 54(12):809-17.
• Ganster C, Shirneshan K, Salinas-Riester G, Braulke F, Schanz J, Platzbecker U, Haase D. Influence of total genomic alteration and chromosomal fragmentation on response to a combination of azacitidine and lenalidomide in a cohort of patients with very high risk MDS. Leuk Res. 2015. 39(10):1079-87.
• Bacher U, Schanz J, Braulke F, Haase D. Leuk Res. 2015. 39(10):1079-87. Rare cytogenetic abnormalities in myelodysplastic syndromes. Mediterr J Hematol Infect Dis. 2015. 7(1):e2015034.
• Schanz J, Haase D, Steuernagel P, Shirneshan K, Bäsecke J. Primary osteomyelofibrosis and an XX-male genotype. Eur J Haematol. 2015. 95(3):254-6.

Publikationen 2014

• Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica. 2015. 100(2):205-13.

Publikationen 2013

• Giagounidis A, Haase D. Morphology, cytogenetics and classification of MDS. Best Pract Res Clin Haematol. 2013. cc26(4):337-53.
• Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.  Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013. 27(10):1988-95.
• Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AA, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. Leuk Res. 2013. 37(8):900-6.
• Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, Haase D. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013. 37(3):327-32.

Publikationen 2012

• Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012. 120(12):2454-65.
• Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012. 30(8):820-9.

Publiaktionen 2011

• Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Leuk Res. 2012. 36(3):264-70.
• Braulke F, Schanz J, Steffens R, Liehr T, Manvelyan M, Chudoba I, Haase D. Two different del(5q) clones in a patient with myelodysplastic syndrome. Leuk Lymphoma. 2011. 52(9):1811-4.
• Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol. 2011. 29(15):1963-70.